CEO: Jay Shepard

Advent Contact: Shahzad Malik

Therapies targeting survival pathways for cancer

Aravive, Inc., is a clinical stage biotechnology company focused on developing new therapies that target important survival pathways for both solid tumors as well as hematologic malignancies. Our primary therapeutic focus is the GAS6-AXL pathway, where AXL receptor signaling plays a critical role in multiple types of malignancies by promoting metastasis and cancer cell survival.

Aravive Biologics and Versartis Complete Merger

Back